Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents (original) (raw)
American Psychiatric Association. Task force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: American Psychiatric Association, 2000 Google Scholar
Molina BS, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry 2009 May; 48(5): 484–500 ArticlePubMed Google Scholar
Barkley RA, Fischer M, Edelbrock CS, et al. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 1990 Jul; 29(4): 546–57 ArticleCAS Google Scholar
Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry 2009 Jan 1; 65(1): 46–54 ArticlePubMed Google Scholar
Merikangas KR, He JP, Burstein M, et al. Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 2010 Oct; 49(10): 980–9 ArticlePubMed Google Scholar
Nolan EE, Gadow KD, Sprafkin J. Teacher reports of DSM-IV ADHD, ODD, and CD symptoms in schoolchildren. J Am Acad Child Adolesc Psychiatry 2001 Feb; 40(2): 241–9 ArticlePubMedCAS Google Scholar
Bussing R, Mason DM, Bell L, et al. Adolescent outcomes of childhood attention-deficit/hyperactivity disorder in a diverse community sample. J Am Acad Child Adolesc Psychiatry 2010 Jun; 49(6): 595–605 PubMed Google Scholar
Price MN, Hyde JS. When two isn’t better than one: predictors of early sexual activity in adolescence using a cumulative risk model. J Youth Adolesc 2009 Sep; 38(8): 1059–71 ArticlePubMed Google Scholar
Brown LK, Hadley W, Stewart A, et al. Psychiatric disorders and sexual risk among adolescents in mental health treatment. J Consult Clin Psychol 2010 Aug; 78(4): 590–7 ArticlePubMed Google Scholar
Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63 Suppl. 12: 10–5 PubMed Google Scholar
Redelmeier DA, Chan WK, Lu H. Road trauma in teenage male youth with childhood disruptive behavior disorders: a population based analysis. PLoS Med 2010; 7(11): e1000369 ArticlePubMed Google Scholar
Pruitt DB, American Academy of Child and Adolescent Psychiatry. Your adolescent: emotional, behavioral, and cognitive development from early adolescence through the teen years. 1st ed. New York: HarperCollins, 1999 Google Scholar
Biederman J, Petty CR, Monuteaux MC, et al. The longitudinal course of comorbid oppositional defiant disorder in girls with attention-deficit/hyperactivity disorder: findings from a controlled 5-year prospective longitudinal follow-up study. J Dev Behav Pediatr 2008 Dec; 29(6): 501–7 ArticlePubMed Google Scholar
Langley K, Fowler T, Ford T, et al. Adolescent clinical outcomes for young people with attention-deficit hyper-activity disorder. Br J Psychiatry 2010 Mar; 196: 235–40 ArticlePubMed Google Scholar
Gau SS, Chong MY, Yang P, et al. Psychiatric and psychosocial predictors of substance use disorders among adolescents: longitudinal study. Br J Psychiatry 2007 Jan; 190: 42–8 ArticlePubMed Google Scholar
Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 1999 Aug; 104(2): e20 ArticlePubMedCAS Google Scholar
Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008 May; 165(5): 604–9 ArticlePubMed Google Scholar
Biederman J, Monuteaux MC, Spencer T, et al. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009 Jul; 124(1): 71–8 ArticlePubMed Google Scholar
Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Jul; 46(7): 894–921 ArticlePubMed Google Scholar
Findling RL, Childress AC, Cutler AJ, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011 Apr; 50(4): 395–405 ArticlePubMed Google Scholar
Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Feb; 28(2): 266–79 ArticlePubMedCAS Google Scholar
Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Jul; 45(7): 817–23 ArticlePubMed Google Scholar
Findling RL, Turnbow J, Burnside J, et al. A randomized, double-blind, multicenter, parallel-group, placebo-controlled, dose-optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectr 2010 Jul; 15(7): 419–30 PubMed Google Scholar
Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2006 Jan; 160(1): 82–90 ArticlePubMed Google Scholar
Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Mar; 109(3): E39 ArticlePubMed Google Scholar
Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/ hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009 Feb; 48(2): 155–65 ArticlePubMed Google Scholar
Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008 Jan; 121(1): e73–84 ArticlePubMed Google Scholar
Wilens T, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012 Jan; 51(1): 74–85 ArticlePubMed Google Scholar
Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011 Feb; 50(2): 171–9 ArticlePubMed Google Scholar
Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011 Jun; 127(6): e1406–13 ArticlePubMed Google Scholar
Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159(11): 1896–901 ArticlePubMed Google Scholar
Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010 Apr; 19(4): 353–64 ArticlePubMed Google Scholar
Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010; 6: 317–27 ArticlePubMedCAS Google Scholar
Adderall XR® [(mixed salts of a single-entity amphetamine product) dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate monohydrate, amphetamine sulfate capsules]. US prescribing information. Wayne (PA): Shire US Inc., 2010
Focalin XR® (dexmethylphenidate hydrochloride extended-release capsules). US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2011
Volkow ND, Fowler JS, Wang G, et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6 Suppl. 1: S31–43 PubMed Google Scholar
Brams M, Muniz R, Childress A, et al. A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect. CNS Drugs 2008; 22(8): 693–704 ArticlePubMedCAS Google Scholar
Silva RR, Muniz R, Pestreich L, et al. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Feb; 47(2): 199–208 ArticlePubMed Google Scholar
Silva RR, Muniz R, Pestreich L, et al. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006 Jun; 16(3): 239–51 ArticlePubMed Google Scholar
Focalin XR (dexmethylphenidate hydrochloride extended-release). US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2010
Wilens TE, Boellner SW, Lopez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008 Jun; 47(6): 700–8 ArticlePubMed Google Scholar
McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006 Feb; 9(3): 476–85 ArticlePubMed Google Scholar
Concerta® (methylphenidate hydrochloride extended-release tablets). US prescribing information. Titusville (NJ): McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2010
Armstrong RB, Damaraju CV, Ascher S, et al. Time course of treatment effect of concerta (OROS® methylphenidate in children with ADHD. J Atten Disord. Epub 2011 Nov 14
Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008 Jun; 165(6): 721–30 ArticlePubMed Google Scholar
Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005 Aug; 9(1): 275–89 ArticlePubMed Google Scholar
Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord 2011 Nov; 15(8): 674–83 ArticlePubMed Google Scholar
Kapvay® (clonidine hydrochloride extended-release tablets, oral). US prescribing information. Atlanta (GA): Shionogi Pharma Inc., 2010
Intuniv (guanfacine extended-release tablets). US prescribing information. Wayne (PA): Shire US Inc., 2009
Strattera® (atomoxetine hydrochloride). US prescribing information. Indianapolis (IN): Eli Lilly and Company, 2011
Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol 2011 Apr; 21(2): 97–110 ArticlePubMedCAS Google Scholar
Dell’Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol 2009 Nov; 19(11): 822–34 ArticlePubMed Google Scholar
Biederman J, Spencer TJ, Newcorn JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007 Jan; 190(1): 31–41 ArticleCAS Google Scholar
Newcorn JH, Spencer TJ, Biederman J, et al. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2005 Mar; 44(3): 240–8 ArticlePubMed Google Scholar
Spencer TJ, Abikoff HB, Connor DF, et al. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Clin Ther 2006 Mar; 28(3): 402–18 ArticlePubMedCAS Google Scholar
Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007 Sep; 46(9): 1119–27 ArticlePubMed Google Scholar
Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 2010 Jun; 49(6): 573–82 PubMed Google Scholar
McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict 2010 Nov–Dec; 19(6): 481–9 ArticlePubMed Google Scholar
Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007 Aug; 17(4): 407–20 ArticlePubMed Google Scholar
Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec 27; 65(12): 1941–9 ArticlePubMedCAS Google Scholar
Vyvanse® (lisdexamfetamine dimesylate capsules). US prescribing information. Wayne (PA): Shire US Inc., 2011
Pringsheim T, Steeves T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 2011; (4): CD007990
Deputy SR. Treatment of ADHD in children with tics: a randomized controlled trial. Clin Pediatr (Phila) 2002 Nov–Dec; 41(9): 736 Article Google Scholar
Castellanos FX, Giedd JN, Elia J, et al. Controlled stimulant treatment of ADHD and comorbid Tourette’s syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997 May; 36(5): 589–96 ArticlePubMedCAS Google Scholar
Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001 Jul; 158(7): 1067–74 ArticlePubMedCAS Google Scholar
McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003 Jun; 42(6): 673–83 ArticlePubMed Google Scholar
Swanson JM, Wigal SB, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 2004 Mar; 113 (3 Pt 1): e206–16 ArticlePubMed Google Scholar
Biederman J, Boellner SW, Childress A, et al. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 2007 Nov 1; 62(9): 970–6 ArticlePubMedCAS Google Scholar
Wigal SB, Kollins SH, Childress AC, et al. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 2009; 3(1): 17 ArticlePubMed Google Scholar
Wigal T, Brams M, Gasior M, et al. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder. Postgrad Med 2011 Mar; 123(2): 169–76 ArticlePubMed Google Scholar
Silva R, Muniz R, McCague K, et al. Treatment of children with attention-deficit/hyperactivity disorder: results of a randomized, multicenter, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull 2008; 41(1): 19–33 PubMed Google Scholar
Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul; 114 (1): e1–8 ArticlePubMed Google Scholar
Hammerness PG, Perrin JM, Shelley-Abrahamson R, et al. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011 Oct; 50(10): 978–90 ArticlePubMed Google Scholar
Murray DW, Arnold LE, Swanson J, et al. A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA). Curr Psychiatry Rep 2008 Oct; 10(5): 424–31 ArticlePubMed Google Scholar
Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 2007 Oct; 17(5): 689–700 ArticlePubMed Google Scholar
Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009 Jun; 19(3): 215–26 ArticlePubMed Google Scholar
Powers RL, Marks DJ, Miller CJ, et al. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Child Adolesc Psychopharmacol 2008 Oct; 18(5): 449–59 ArticlePubMed Google Scholar
Increasing prevalence of parent-reported attention-deficit/ hyperactivity disorder among children: United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010 Nov 12; 59 (44): 1439–43
Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004 May; 43(5): 559–67 ArticlePubMed Google Scholar